助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   peripheral nerve toxicity 的翻译结果: 查询用时:0.184秒
图标索引 在分类学科中查询
所有学科
更多类别查询

图标索引 历史查询
 

peripheral nerve toxicity
相关语句
  周围神经毒性
     The main side effects were myelosppression, GI and peripheral nerve toxicity and phlebitis.
     腺癌疗效比鳞癌稍好 ,主要毒副反应为骨髓抑制、消化道反应、周围神经毒性及静脉炎。
短句来源
     The main side effects were myelosuppresion,gastrointestinal reation and peripheral nerve toxicity and phlebitis.
     主要毒副反应为骨髓抑制、胃肠道反应、周围神经毒性及静脉炎。
短句来源
  相似匹配句对
     Advances in peripheral nerve repair
     周围神经损伤修复方法研究进展
短句来源
     Repair of Peripheral Nerve Injury
     周围神经损伤的修复
短句来源
     It is of high toxicity.
     该菌具有较强的毒力。
短句来源
     Toxicity of Vitamine
     维生素的毒性
短句来源
     The Toxicity of Acrylamide
     丙烯酰胺毒性研究进展
短句来源
查询“peripheral nerve toxicity”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  peripheral nerve toxicity
Certain patients, however, may be at high risk for peripheral nerve toxicity due to genetic factors or another underlying neuropathy.
      


Purpose:Clinical research has been done to show whether continuous infusion of navelbine can increase curative effect and decrease toxicity.Methods:Patients studied were non operable NSCLC and recurrent or metastatic breast cancer. Navelbine is given through a catheter in the venae subclavia by continuous infusion for 24 hours. Regimen:NVB 10 mg/iv/day 1+NVB 10 mg/iv continuous infusion 24 h/day 1—5+DDP 40 mg/iv 2h/day 1—3+Gransetron 3 mg/iv day1,3,5 given every 21 days. Results:Among 47 patients 35 patients...

Purpose:Clinical research has been done to show whether continuous infusion of navelbine can increase curative effect and decrease toxicity.Methods:Patients studied were non operable NSCLC and recurrent or metastatic breast cancer. Navelbine is given through a catheter in the venae subclavia by continuous infusion for 24 hours. Regimen:NVB 10 mg/iv/day 1+NVB 10 mg/iv continuous infusion 24 h/day 1—5+DDP 40 mg/iv 2h/day 1—3+Gransetron 3 mg/iv day1,3,5 given every 21 days. Results:Among 47 patients 35 patients were NSCLC and 12 patients were breast cancer. Average age was 58.9 years. Of the NSCLC patients, 12 were squamous cell carcinoma and 23 patients were adenocarcinoma; two patients were stage Ⅱ and 19 patients stage Ⅲ, 19 patients stage Ⅳ. All of the breast cancer cases were infiltrative duct carcinoma. Three patients were stage Ⅱ and nine patients were stage Ⅳ. Of the 47 patients, 44 patients were evaluable for response and 47 patients for toxicity. Response rate of NSCLC was 57%(19 pr) and breast cancer 63% (1 cr, 6 pr). Main toxicity was granulocytopenia and vomiting. WHO Ⅲ—Ⅳ grade granulocytopenia was 40% and vomiting 6.4%. Peripheral nerves toxicity was mild and only 6.4% patients had WHO I grade peripheral sensory nerve damage. No patients had severe nerve toxicity such as enteroplegia.Conclusions:Comparison of continuous infusion Navelbine and Cisplatin with classic usage of navelbine for management of NSCLC and breast cancer showed increased response rate and decreased toxicity. Administration through catheter venae subclavia can avoid chemo phlebitis. [

目的 :临床研究去甲长春花碱 (诺维本 ,Navelbine,NVB)持续静脉输注是否可以提高疗效并减轻毒副反应。方法 :转移或复发的晚期乳腺癌以及不能手术的Ⅲ—Ⅳ期非小细胞肺癌的病人。其中去甲长春花碱的给药方式采用注射泵通过锁骨下深静脉置管进行 2 4小时持续给药。治疗方案 :NVB 10mg静脉一次推注第 1天 ,NVB10mg静脉持续滴注 2 4小时 ,第 1— 5天 ,DDP 40mg静脉滴注 2小时第 1— 3天 ,盐酸格拉司琼 3mg静脉推注第 1,3,5天。 2 1天为 1周期 ,2周期后评价疗效。结果 :47例病人中非小细胞肺癌 35例 ,乳腺癌 12例。平均年龄为 5 8.9岁。非小细胞肺癌中鳞癌病人 12例 ,腺癌病人 2 3例 ;Ⅱ期 2例 ,Ⅲ期 19例 ,Ⅳ期 14例 ;乳腺癌病人均为浸润型导管癌 ,其中Ⅲ期为 3例 ,Ⅳ期为 9例。可评价疗效病人 44例。非小细胞肺癌病人 19例达PR ,总有效率为 5 7%。乳腺癌病人 1例达CR ,6例达PR ,总有效率为 6 3%。可评价毒性反应病人 47例。主要毒性反应为白细胞下降及轻度的消化道反应。其中白细胞Ⅲ—Ⅳ度毒性达 5 1% ,粒...

目的 :临床研究去甲长春花碱 (诺维本 ,Navelbine,NVB)持续静脉输注是否可以提高疗效并减轻毒副反应。方法 :转移或复发的晚期乳腺癌以及不能手术的Ⅲ—Ⅳ期非小细胞肺癌的病人。其中去甲长春花碱的给药方式采用注射泵通过锁骨下深静脉置管进行 2 4小时持续给药。治疗方案 :NVB 10mg静脉一次推注第 1天 ,NVB10mg静脉持续滴注 2 4小时 ,第 1— 5天 ,DDP 40mg静脉滴注 2小时第 1— 3天 ,盐酸格拉司琼 3mg静脉推注第 1,3,5天。 2 1天为 1周期 ,2周期后评价疗效。结果 :47例病人中非小细胞肺癌 35例 ,乳腺癌 12例。平均年龄为 5 8.9岁。非小细胞肺癌中鳞癌病人 12例 ,腺癌病人 2 3例 ;Ⅱ期 2例 ,Ⅲ期 19例 ,Ⅳ期 14例 ;乳腺癌病人均为浸润型导管癌 ,其中Ⅲ期为 3例 ,Ⅳ期为 9例。可评价疗效病人 44例。非小细胞肺癌病人 19例达PR ,总有效率为 5 7%。乳腺癌病人 1例达CR ,6例达PR ,总有效率为 6 3%。可评价毒性反应病人 47例。主要毒性反应为白细胞下降及轻度的消化道反应。其中白细胞Ⅲ—Ⅳ度毒性达 5 1% ,粒细胞下降Ⅲ—Ⅳ度毒性达 40 %。消化道反应较为轻微 ,Ⅲ—Ⅳ度呕吐只占 6 .4%。神经毒性相当轻微 ,只有 6 .4%的病人有Ⅰ度的感觉神经损伤 ,没有病人出现如肠麻庳的严重神经毒性。结论 :去甲长春花碱持

To evaluate the short term effect of cisplatin_based combined chemotherapy NP regimen and MVP regimen for non_small cell lung cancer(NSCLC). One hundred and six cases of advanced NSCLC were treated with either vinorelbine/cisplatin (NP) (n=48) or mitomycin/vindesine/cisplatin (MVP) (n=58) regimen. In NP Group 12 cases were phase Ⅲb and 36 cases are phase Ⅳ. There were 12 cases of squamous carcinoma and 30 of adenocarcinoma and 6 of mixed type(NVB 25mg/m2 iv day 1,8; cisplatin 90mg/m2 iv infusion day 1). In...

To evaluate the short term effect of cisplatin_based combined chemotherapy NP regimen and MVP regimen for non_small cell lung cancer(NSCLC). One hundred and six cases of advanced NSCLC were treated with either vinorelbine/cisplatin (NP) (n=48) or mitomycin/vindesine/cisplatin (MVP) (n=58) regimen. In NP Group 12 cases were phase Ⅲb and 36 cases are phase Ⅳ. There were 12 cases of squamous carcinoma and 30 of adenocarcinoma and 6 of mixed type(NVB 25mg/m2 iv day 1,8; cisplatin 90mg/m2 iv infusion day 1). In MVP group 8 cases were phase Ⅲb and 50 cases are phase Ⅳ. There were 14 cases of squamous carcinoma and 36 of adenocarcinoma and 8 of mixed type(MMC 6mg/m2 iv day 1; VDS 3mg/m2 iv day1,8; cisplatin 90mg/m2 iv infusion day 1). The two regimens were given every three weeks as one cycle.Effect and toxicity were evaluated after two cycles. The response rates of NP and MVP were 37.5% and 32.1%, respectively. There were no significant difference between the two regimens (P>0.05). The response rate in adenocarcinoma was higher than that in squamous carcinoma. The main side effects were myelosppression, GI and peripheral nerve toxicity and phlebitis.[Conclusion] NP and MVP regimens maybe as the first line chemotherapy regimens for NSCLC,and also applied in the treatment of refractory advanced NSCLC and community hospitals.

[目的]评价含顺铂的联合方案NP与MVP对复治的晚期非小细胞肺癌的近期疗效。[方法]106例晚期非小细胞肺癌随机被分为两组。NP组48例 ,其中Ⅲb期12例 ,Ⅳ期36例 ,鳞癌12例 ,腺癌30例 ,鳞腺混合型6例 ,采用诺维本25mg/m2 静脉推注 ,第1,8天 ;顺铂90mg/m2 静脉滴注 ,第1天 (配合水化 )。MVP组58例 ,其中Ⅲb期8例 ,Ⅳ期50例 ,鳞癌14例 ,腺癌36例 ,鳞腺混合型8例 ,采用丝裂霉素6mg/m2 静脉推注 ,第1天 ;VDS3mg/m2 静脉推注 ,第1,8天 ;顺铂90mg/m2 ,静脉滴注 ,第1天 (配合水化 )。两方案均为每3周为1周期 ,治疗2周期后评价疗效与毒副反应。[结果]NP组有效率(RR)为37.5% ,MVP组RR为31.0% ,差异无显著性 (P>0.05)。腺癌疗效比鳞癌稍好 ,主要毒副反应为骨髓抑制、消化道反应、周围神经毒性及静脉炎。目前均能采取相应的防治措施。[结论]NP与MVP方案均为治疗非小细胞肺癌的第一线治疗方案 ,也适用于复治的晚期非小细胞肺癌 ,更适用于基层医院的治疗

Objective To evaluate the effect and toxicity of oxaliplatin combined with 5-fluorouracil and folinic acid (FOLFOX4 regimen) as second-line treatment for the patients with advanced gastric cancer(AGC). Methods 34 cases with advanced gastric cancer and received Taxane regimen chemotherapy before, were treated with FOLFOX4 regimen. Results 33 patients were evaluated for clinical response. The overall response rate was 21.2% (CR 1, PR 6, SD 14 and PD 12). The median duration of response was 5 months. Median TTP...

Objective To evaluate the effect and toxicity of oxaliplatin combined with 5-fluorouracil and folinic acid (FOLFOX4 regimen) as second-line treatment for the patients with advanced gastric cancer(AGC). Methods 34 cases with advanced gastric cancer and received Taxane regimen chemotherapy before, were treated with FOLFOX4 regimen. Results 33 patients were evaluated for clinical response. The overall response rate was 21.2% (CR 1, PR 6, SD 14 and PD 12). The median duration of response was 5 months. Median TTP was 4.2 months. Median survival time was 6 months. 34 patients were evaluated for toxicity. The major reaction was bone suppression, nausea/vomiting and peripheral nerve toxicity. Conclusion The FOLFOX4 regimen is an active and good regimen as the second line treatment for AGC, with favorable toxicity profile and deserves further evaluation in randomized studies.

目的评价奥沙利铂联合亚叶酸钙和5氟脲嘧啶组成的FOLFOX4方案二线治疗晚期胃癌的有效性及安全性。方法34例经过紫杉类药物为主方案治疗后失败的晚期胃癌患者,给予FOLFOX4方案化疗,治疗后按WHO标准进行评价。结果全组34例,可评价疗效的有33例,其中CR1例,PR6例,SD14例,PD12例,RR率为21.2%,中位缓解时间5个月,中位TTP4.2个月,中位生存期6个月;可评价毒性的有34例,毒副反应主要是骨髓抑制、恶心、呕吐等消化道反应及外周感觉神经毒性,经对症处理,可以逆转。结论FOLFOX4方案二线治疗晚期胃癌疗效肯定,安全性较好,值得深入研究。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关peripheral nerve toxicity的内容
在知识搜索中查有关peripheral nerve toxicity的内容
在数字搜索中查有关peripheral nerve toxicity的内容
在概念知识元中查有关peripheral nerve toxicity的内容
在学术趋势中查有关peripheral nerve toxicity的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社